news
New oral drug shrinks KRAS G12D tumors in early trial
Researchers just published Phase 1 trial data for GFH375, an oral drug targeting the KRAS G12D mutation, showing it shrank tumors in 47% of 45 patients with advanced solid cancers. Lead author Dr. Jian Li at Sun Yat-sen University presented the findings, a promising step for a notoriously hard-to-treat cancer pathway.
Researchers just published Phase 1 trial data for GFH375, an oral drug targeting the KRAS G12D mutation, showing it shrank tumors in 47% of 45 patients with advanced solid cancers. Lead author Dr. Jian Li at Sun Yat-sen University presented the findings, a promising step for a notoriously hard-to-treat cancer pathway.
The architecture take
Okay, this is big for people with advanced KRAS G12D cancers. For years, KRAS was considered 'undruggable,' a protein mutation involved in about a quarter of all human tumors. This new oral inhibitor, GFH375, directly targets the G12D variant, which is one of the most common KRAS mutations, often found in pancreatic and colorectal cancers.
The early data, while from a small Phase 1 study, shows real tumor shrinkage in nearly half the patients. That’s a significant response rate for a population with previously treated, advanced disease. It means less cancer load, less inflammation, and potentially more life. What I'm watching for is how this impacts quality of life metrics, beyond just tumor size. A new oral option is easier to manage than IV therapies, which matters for chronic disease. It’s a win for targeted therapy, signaling that even the toughest pathways can eventually yield to smart drug design.